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1. Introduction 
Amyloid substance is a complex proteinaceous 
material found in the tissues of patients with the dis- 
ease amyloidosis. Recently we have presented evi- 
dence that there are two chemically distinct kinds 
of amyloid substance, one associated with the clas- 
sical inflammation-related amyloidosis and another, 
frequently designated atypical or paramyloid, oc- 
curring with tumors such as multiple myeloma or 
without evident pre-existing disease [l] . The classi- 
cal, or inflammation-associated, substance is dis- 
tinguished by: a) instability to alkali of its charac- 
teristic Congo red binding capacity; b) its amino acid 
composition and c) the presence of a major protein 
constituent, amyloid protein A. The family of pro- 
teins comprising amyloid protein A has a molecular 
weight range of 6000-8000 and a characteristic 
amino acid composition [2] ; in addition, human 
amyloid protein A has the capacity to bind Congo 
red and exhibits the characteristic hyperchromism 
and spectral changes previously described for amy- 
loid substance [ 1] . In this communication we com- 
pare the chromatographic and electrdphoretic prop- 
erties, the amino acid composition and the 24 amino 
acid N-terminal sequence of the human- and monkey- 
derived protein A of amyloid substance. 
2. Materials and methods 
Amyloid substance was concentrated and purified 
from liver tissue as previously described [ 11. The 
human material was obtained from a patient who 
had classical generalized amyloidosis associated with 
tuberculosis. The clinical data on this case, designated 
in our series as A-4, have been recorded elsewhere 
[ 1 ] . The liver of a monkey (Macaca mdatta) having 
amyloidosis associated with a chronic granulomatous 
disease presumed to be a tuberculous infection [3] 
was kindly provided us by Dr. Boris Ruebner of 
the National Regional Primate Center at Davis, Cali- 
fornia. More than 50% of the tissue mass in each 
of the livers was estimated by microscopy to be 
amyloid substance. In both instances the amyloid 
substance exhibited the characteristic staining with 
crystal violet and Congo red and had the expected 
abundance of microfibrils when examined in the 
electron microscope. 
To prepare the major constituent, protein A, the 
purified amyloid substances were extracted with 6 M 
urea - 0.01 M HCOONa - 0.5 M HCOOH, pH 3.0 
(urea-formate buffer). Each 100 mg of dry starting 
material was suspended in 4 ml of buffer. The sus- 
pensions were stirred overnight at 4” and then centri- 
fuged at 25,000 g for 30 min. Extracts were frac- 
tionated on G-100 Sephadex in the urea-formate 
buffer (fig. 1). The slower portion (IVb) of the major 
fraction obtained from each sample was dialyzed 
against Hz0 in acetylated cellulose casing [l] until 
the concentration of urea had been reduced to about 
0.1 M, and then lyophilized. The partly purified A 
proteins were further purified and freed of the bulk 
of the remaining urea by chromatography on 
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Fig. 1. Fractionation of extracts of human (H) and monkey 
(M) amyloid-substance concentrates on G-100 Sephadex in 
urea-formate buffer, pH 3. Human sample (12.4 ml derived 
from 400 mg purified amyloid substance) passed through a 
5.0 X 88 cm column at a flow rate of 47 ml/hr; monkey sam- 
ple (6.1 ml derived from 185 mg purified amyloid substance), 
through a 2.5 X 63 cm column at a flow rate of 12 ml/hr. 
Numbers at top indicate relative amounts of material con- 
tained in pooled effluent fractions (I-VI) according to ab- 
sorption measurements at 289 nm (pH > 12). 
Table 1 
Amino acid composition* of human and monkey amyloid 
protein A. 
Amino 
acid 
Human 
(not 
oxidized)a 
Human Monkey 
(oxidized) b (oxidized) b 
Lys 2.8 
His 2.2 
Arg 10.8 
Asp 13.4 
Thr 0.1 
Ser 7.5 
Glu 7.4 
Pro 1.5 
GlY 12.2 
Ala 16.7 
cys/2 0.1 
Val 1.4 
Met 2.8 
Ile 3.8 
Leu 1.5 
Tyr 5.5 
Phe 8.2 
Trpe 2.3 
HYP 0.0 
2.8 5.4 
2.0 2.7 
10.7 7.7 
14.1 15.4 
0.0 1.3 
7.3 6.3 
1.2 9.6 
1.4 1.3 
12.2 10.9 
17.5 15.5 
o.oc o.oc 
1.3 2.0 
2.8d 2.5d 
3.2 2.0 
1.5 4.0 
5.4 6.0 
7.7 3.7 
2.8f 3.7f 
o.of o.of 
Residues per 100 found. 
Mean or extrapolated values derived from hydrolysis 
times of 20,40 and 70 hr in constant boiling HCI at 
108- 110” ; sample material isolated from washed tissue 
by extraction with 6 M urea, pH 3.5 [I]. 
24-hr hydrolysis of sample material oxidized with per- 
formic acid [ 81. 
Determined as cysteic acid; total cysteic acid < 0.05 
residue per 100. 
Determined as methionine sulfone. 
Spectrophotometric estimation 191. 
Estimated in non-oxidized sample. 
A X 65 cm columns of G-50 Sephadex equilibrated 
with 0.05 M acetic acid, the developing solvent [2]. 
In each instance a single slightly asymmetric peak was 
obtained. The main portion of this rechromatographed 
fraction was recovered, adjusted to pH 5 to induce pre- 
cipitation of the protein, dialyzed free of residual urea, 
and lyophilized. 
The N-terminal amino acid sequence of the two 
proteins was determined in a Beckman Model 890 
Sequencer by an adaptation [4] of the method of 
Edman and Begg [S] . 
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Fig. 2. Electrophoresis of human (H) and monkey (M) amyloid protein A in polyacrylamide gel containing 5 M urea at pH 3, 
according to our adaptation of the method.of Takayama et al. [6], as modified by Senior and MacLennan [ 71. Human sample, 
20 ~g in 5 ~1; monkey sample, 40 ~18 in 10 ~1. Arrow indicates direction of migration (cathodic). Migration time, 4 hr at 120 V; 
gel length, 85 mm; stain, Coomassie blue. 
3. Results 
Of the purified amyloid substance of the human 
case 75-80% was found to be soluble in the urea- 
formate solvent when used as described; as shown 
in fig. 1, 5 1% of this soluble portion was recovered 
in pool IV (a + b), according to optical absorption 
at 289 nm of aliquots adjusted to pH > 12. Of the 
monkey material 65-70% was found to be soluble 
in the urea-formate buffer, and 75% appeared in 
pool IV (fig. 1). According to electrophoretic anal- 
ysis, the material in pool IV from both species is 
almost entirely protein A; electrophoretograms of 
the final protein preparations, i.e., after passage 
through G-50 Sephadex, are shown in fig. 2. The 
proteins derived from the human and from the 
monkey amyloid substances have nearly identical 
electrophoretic mobilities. The protein of human 
origin shows a major band with a faint but distinct 
trailing shadow; that from the monkey shows two 
distinct components, the leading one being the more 
intensely stained. In addition, the monkey protein 
shows a faint slower band. 
Amino acid compositions of human and monkey 
amyloid protein A are clearly similar, as shown in 
table 1. They share the characteristic features of 
low or absent threonine, low proline and lack of 
cysteine, cystine, and hydroxyproline. Both pro- 
teins contain substantial amounts of alanine, 
glycine, and amino acids with acidic, basic, and 
aromatic side chains. 
The amino acid sequences of the N-terminal 
24 amino acids of the human and the monkey pro- 
teins are shown in fig. 3. The sequences are identi- 
cal with the exception of conservative replacements 
at positions 3 and 11, which seem entirely compat- 
ible with other known evolutionary changes and 
with the preservation of structural-functional 
characteristics of proteins. In the human case, 13% 
of the purified protein A lacks amino acids 1, 2 and 
3. This appears to be compatible with the presence 
of a trailing shadow in the electrophoretic pattern 
of the human protein. In the instance of the monkey 
amyloid protein A approximately 22% of the sam- 
ple lacks the N-terminal arginine, and the electro- 
phoretic pattern at pH 3 exhibits a discrete second 
band of a lesser staining than the leading band. A 
third, slower moving band is visible in the monkey 
material and this may represent another larger and/ 
or less positively charged but related peptide. In- 
spection of the experimental sequence data indicates 
that the level of contamination by extraneous pro- 
teins with a free N-terminal probably does not 
exceed 2% in either of the two protein A prepara- 
tions. 
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1 
Human: Arg - 
bC 
Monkey: Arg - 
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2 3ai 4 5 6 7 8 9 10 11 12 
Ser - Phe - phe - Ser - Phe - Leu - Gly - Glu - Ala - Phe - Asp - 
Ser - Trp - Phe - Ser - Phe - Leu - Gly - Glu - Ala - Tyr - Asp - 
Human: 
13 14 15 16 17 18 19 20 21 22' 23 24 
Gly - Ala - Arg- Asp - Met - Trp - Arg - Ala - Tyr - Ser - Asp - Met - 
Monkey: Gly- Ala -Arg -Asp -Met- Trp - Arg - Ala - Tyr - Ser - Asp - Met - 
a Approximately 13% of the human amyloid protein A lacks the N-terminal Arg.aSercJPhe. 
b Approximately 22% of the monkey amyloid protein A lacks the N-terminal Arg. 
' Identification of Ser at position 22 in both chains should be considered tentative. 
Fig. 3. N-terminal amino acid sequences of human and monkey amyloid protein A. 
4. Conclusion 
The data indicate that in cases of the typical or 
classical variety (i.e., the variety associated with 
chronic inflammation) amyloid substance has a 
major component which is homologous in man and 
monkey. Thus far we have had the opportunity to 
examine amyloid substances from eight cases of 
amyloidosis of this type in human beings and have 
found them to be essentially the same according 
to amino acid composition, alkali instability of the 
Congo red binding, and the presence of protein A 
[ 1, 21. Four cases of monkey amyloidosis of this 
variety have shown essentially identical amyloid 
substance by the same criteria [2]. 
Amyloidoses of the “atypical” variety, that is 
those associated with tumors and multiple myeloma, 
and the so-called primary kind, can be distinguished 
chemically from the typical inflammation-related 
variety [ 11. It has recently been suggested that in 
some cases amyloid proteins represent N-terminal 
fragments of light chains of immunoglobulins or of 
light chains with internal deletions [lo]. While this 
may be true for certain types of paramyloidosis, it 
does not seem to be true for the classical variety, 
172 
because protein A of “typical” amyloid substance 
accounts for 50% or more of the recoverable mate- 
rial of purified amyloid substance in both man and 
monkey and, as we have shown elsewhere [ 1 ] , 
carries the Congo red binding marker of amyloid 
substance. Amyloid protein A appears to be a new 
protein since, to our knowledge, no peptide having 
the amino acid sequence reported here has been 
described in the literature. Further study of this 
protein, or family of proteins, will provide us with 
some new biological insights as we determine its 
source, structure and function. 
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